• Recruiting

NCT03767257: Phase 2: A Study of Colesevelam for Lenalidomide-Associated Diarrhea

NCT03767257: Phase 2: A Study of Colesevelam for Lenalidomide-Associated Diarrhea


Colesevelam

NCT03767257: Phase 2: A Study of Colesevelam for Lenalidomide-Associated Diarrhea


The purpose of this study is to test the safety of colesevelam and find out what effects, if any, colesevelam has on lenalidomide associated diarrhea in participants with multiple myeloma on lenalidomide maintenance.


Sponsor

Memorial Sloan Kettering Cancer Center

 

ClinicalTrials.gov Identifier: NCT03767257

Official Title: A Phase 2 Study of Colesevelam for Lenalidomide-Associated Diarrhea

First Posted : December 6, 2018


Click here to see details on ClinicalTrials.gov

 

Drug: Colesevelam Pill

 

Colesevelam

Colesevelam (Code C78056)

Colesevelam

COLESEVELAM

 

Locations

United States, New Jersey

United States, New York




Posts Archive